Skip to content
Checking…
All public datasets

Public dataset

Recorded source agreement and disagreement

Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.

What this does not mean: agree can mean only that sources print the same normalized reading; it is not clinical-context equivalence, independent replication, or proof. differ requires matching structured context and disjoint comparable values. not_comparable and insufficient_context are not disagreement.
Public rows
1,681
Generated
Schema version
source-consensus/2

Coverage

What this run contains

Compared medicine fields
1,681
Agree
1,282
Differ
0
Not comparable
12
Insufficient context
387
Fields represented
5
bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution

Method

How the rows were made

  1. Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
  2. One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
  3. Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
  4. not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
  5. The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
  6. Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
  7. documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.

Limits

Read these before using a row

  • Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
  • The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
  • Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
  • Only the recorded fields and source documents in this snapshot are compared.
  • A source count is the number of retained source records in the row, not a count of independent experiments.

Provenance

Source examples

abacavir · bioavailability · agree

15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
The geometric mean absolute bioavailability of the tablet was 83%.

alemtuzumab · volumeOfDistribution · not_comparable

2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)
Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).

abiraterone · halfLife · insufficient_context

31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.

Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Schema

Fields in the public projection

FieldTypeMeaning
medicineSlugstringStable RNAWiki medicine route key.
fieldstringRecorded pharmacokinetic field being compared.
comparisonStatestringagree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero.
comparisonReasonsstring[]Deterministic codes explaining the state.
documentsExaminednumberRecorded source documents considered for the field.
sourceCountnumberRecorded source readings represented.
agreementRatenumberShare represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability.
readingsconsensus-reading[]Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt.

Reader

Search and filter the rows

Case-insensitive text search over the public fields named for this dataset.

Exact comparability state.

Exact recorded field key.

Clear

Showing 311320 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

  1. Projected row 311

    Medicine slug
    cladribine
    Compared field
    volumeOfDistribution
    Comparison state
    not_comparable
    Reason codes
    • DENOMINATOR_MISMATCH
    Documents examined
    8
    Source count
    8
    Agreement rate
    0.5
    Recorded readings
    1. 4.5±2.8 L/kg

      Numeric value
      4.5
      Unit
      L/kg
      Source records
      4

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 4 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:71c39b37-33b5-42e1-bf4f-93ff751cc7fe (opens source in a new tab)

        Cladribine label

        Version not recorded · Effective date not recorded

        Mean values for clearance and steady-state volume of distribution were 978±422 mL/h/kg and 4.5±2.8 L/kg, respectively.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a2592a9b-bca6-4a5a-89c2-855a0634d5fe (opens source in a new tab)

        Cladribine label

        Version not recorded · Effective date not recorded

        Mean values for clearance and steady-state volume of distribution were 978 ± 422 mL/h/kg and 4.5 ± 2.8 L/kg, respectively.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f538cba9-001a-4a21-e053-2a95a90a00ec (opens source in a new tab)

        Cladribine label

        Version not recorded · Effective date not recorded

        Mean values for clearance and steady-state volume of distribution were 978±422 mL/h/kg and 4.5±2.8 L/kg, respectively.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5736aecc-cc1d-47dd-86c0-5fb2e9d70f61 (opens source in a new tab)

        Cladribine label

        Version not recorded · Effective date not recorded

        Mean values for clearance and steady-state volume of distribution were 978 ± 422 mL/h/kg and 4.5 ± 2.8 L/kg, respectively.
    2. 480 to 490 liters

      Numeric value
      480
      Unit
      L
      Source records
      4

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 4 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f1d650a5-4205-720b-f39b-4213277b6612 (opens source in a new tab)

        Cladribine label

        Version not recorded · Effective date not recorded

        Distribution Cladribine mean apparent volume of distribution ranges from 480 to 490 liters.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e0b363cb-db83-44d6-89d0-1f7176be7459 (opens source in a new tab)

        Cladribine label

        Version not recorded · Effective date not recorded

        Distribution Cladribine mean apparent volume of distribution ranges from 480 to 490 liters.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9c75e30a-a410-40f1-b653-04d532bd9144 (opens source in a new tab)

        Cladribine label

        Version not recorded · Effective date not recorded

        Distribution Cladribine mean apparent volume of distribution ranges from 480 to 490 liters.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:407c52d5-6498-7da5-da35-acc9ca73ced3 (opens source in a new tab)

        Cladribine label

        Version not recorded · Effective date not recorded

        Distribution Cladribine mean apparent volume of distribution ranges from 480 to 490 liters.
  2. Projected row 312

    Medicine slug
    clarithromycin
    Compared field
    bioavailability
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    42
    Source count
    35
    Agreement rate
    1
    Recorded readings
    1. 50%

      Numeric value
      50
      Unit
      %
      Source records
      35

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 35 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fa69ea92-0b41-43fb-918f-ed80e0dedf04 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption The absolute bioavailability of 250 mg clarithromycin tablets was approximately 50%.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a12e4d38-e0f8-4467-a26c-bb25a342aa92 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption Clarithromycin Tablets The absolute bioavailability of 250 mg clarithromycin tablets was approximately 50%.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9bf207c0-86eb-4f3b-92e7-f65f3fccd5a7 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption The absolute bioavailability of 250 mg clarithromycin tablets was approximately 50%.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b98b02bb-2609-49a0-b29f-e5911aa0cbc1 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption Clarithromycin Tablets The absolute bioavailability of 250 mg clarithromycin tablets was approximately 50%.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d836ae7e-fdbf-4dcb-a90d-ede1dcbc3e67 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption The absolute bioavailability of 250 mg clarithromycin tablets was approximately 50%.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9aaffb41-408c-4372-8fd5-1d649450c0e9 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption The absolute bioavailability of 250 mg clarithromycin tablets was approximately 50%.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2d6cfd87-9b8c-bba9-e063-6294a90aff5a (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption Clarithromycin Tablets The absolute bioavailability of 250 mg clarithromycin tablets was approximately 50%.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0c7d8391-50ef-4827-abe6-e0fc0c2f1636 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption The absolute bioavailability of 250 mg clarithromycin tablets was approximately 50%.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:471f638a-9dd1-09d3-e063-6294a90a2d4f (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption The absolute bioavailability of 250 mg clarithromycin tablets was approximately 50%.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:268d21f9-02c9-41b0-9487-7968ea12720d (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption Clarithromycin Immediate-Release Tablets The absolute bioavailability of 250 mg clarithromycin tablets was approximately 50%.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9143b79c-4c79-43ac-e053-2995a90ad708 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption The absolute bioavailability of 250 mg clarithromycin tablets was approximately 50%.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1d6f5a9d-51b2-4e0d-b573-ccf08fe6ea23 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption The absolute bioavailability of 250 mg clarithromycin tablets was approximately 50%.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:81c0c69e-b1ae-42f3-9e85-09b8daa75d8d (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption The absolute bioavailability of 250 mg clarithromycin tablets was approximately 50%.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:88c7ded8-333c-408d-b693-a72881710f59 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption The absolute bioavailability of 250 mg clarithromycin tablets was approximately 50%.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0c4db97f-f4c9-4cac-9f12-9db1d967ebeb (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption The absolute bioavailability of 250 mg clarithromycin tablets was approximately 50%.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ba216276-b0bd-420a-9e0d-090bdfcc2460 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption The absolute bioavailability of 250 mg clarithromycin tablets was approximately 50%.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f98aacb4-2f01-3e94-e053-6294a90a9aa0 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption Clarithromycin Tablets The absolute bioavailability of 250 mg clarithromycin tablets was approximately 50%.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0be243c6-de02-45dd-8210-cab1bbc8dfa7 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption Clarithromycin Tablets The absolute bioavailability of 250 mg clarithromycin tablets was approximately 50%.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9d5848f0-e9f0-4112-a7ca-bcc8ea2e69c6 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption The absolute bioavailability of 250 mg clarithromycin tablets was approximately 50%.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:59ebe6cb-c830-45c7-8242-52f9f42a90a0 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption The absolute bioavailability of 250 mg clarithromycin tablets was approximately 50%.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:27e02b77-4332-49e0-8d0c-a072cf5dff92 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption Clarithromycin Tablets The absolute bioavailability of 250 mg clarithromycin tablets was approximately 50%.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1cb8a78a-0f07-49e8-a23e-a77628006209 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption The absolute bioavailability of 250 mg clarithromycin tablets was approximately 50%.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9eb306e0-ccfb-418c-82ca-204f20a788f7 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        The absolute bioavailability of 250 mg clarithromycin tablets was approximately 50%.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d0a66646-6774-4fc6-9b26-a98c3a5df274 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption The absolute bioavailability of 250 mg clarithromycin tablets was approximately 50%.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:de33ba3a-9df1-4076-8d5f-b603d2698096 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption Clarithromycin Immediate-Release Tablets The absolute bioavailability of 250 mg clarithromycin tablets was approximately 50%.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1920f943-bbf1-cfd9-7475-96a35680a9e0 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption The absolute bioavailability of 250 mg clarithromycin tablets was approximately 50%.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cde51c9f-f7b8-413f-8b8e-e56370cd5754 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption Clarithromycin Immediate-Release Tablets The absolute bioavailability of 250 mg clarithromycin tablets was approximately 50%.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:adba78c2-9e51-4bed-8c6a-6f977f79c40c (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption Clarithromycin Tablets The absolute bioavailability of 250 mg clarithromycin tablets was approximately 50%.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d22bd12c-737b-4aab-e053-2995a90aff60 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        12.1 Mechanism of Action Clarithromycin is a macrolide antimicrobial drug [see Microbiology (12.4)]. 12.3 Pharmacokinetics Absorption Clarithromycin Tablets The absolute bioavailability of 250 mg clarithromycin tablets was approximately 50%.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:25debd85-0840-4f8d-9898-027772061dd2 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption The absolute bioavailability of 250 mg clarithromycin tablets was approximately 50%.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3ba1da51-ba5b-323f-e063-6294a90a0333 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        12.1 Mechanism of Action Clarithromycin is a macrolide antimicrobial drug [see Microbiology (12.4)]. 12.3 Pharmacokinetics Absorption The absolute bioavailability of 250 mg clarithromycin tablets was approximately 50%.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:99d2fd6b-39ca-42f9-ad06-30e7fbc22c47 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption Clarithromycin Immediate-Release Tablets The absolute bioavailability of 250 mg clarithromycin tablets was approximately 50%.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:28f60574-4ecd-441c-aebe-5b1d18033ef6 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption Clarithromycin Tablets The absolute bioavailability of 250 mg clarithromycin tablets was approximately 50%.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b1bdf526-4f16-4130-b614-4cb678f060d7 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        The absolute bioavailability of 250 mg clarithromycin tablets was approximately 50%.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4d42821d-ce7a-7d64-e063-6294a90a0875 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption The absolute bioavailability of 250 mg clarithromycin tablets was approximately 50%.
  3. Projected row 313

    Medicine slug
    clarithromycin
    Compared field
    halfLife
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    42
    Source count
    40
    Agreement rate
    0.95
    Recorded readings
    1. 3 hours

      Numeric value
      3
      Unit
      hours
      Source records
      38

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 38 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fa69ea92-0b41-43fb-918f-ed80e0dedf04 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        The elimination half-life of clarithromycin was about 3 hours to 4 hours with 250 mg administered every 12 hours but increased to 5 hours to 7 hours with 500 mg administered every 8 hours to 12 hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a12e4d38-e0f8-4467-a26c-bb25a342aa92 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        The elimination half-life of clarithromycin was about 3 hours to 4 hours with 250 mg administered every 12 hours but increased to 5 hours to 7 hours with 500 mg administered every 8 hours to 12 hours.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9bf207c0-86eb-4f3b-92e7-f65f3fccd5a7 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        The elimination half-life of clarithromycin was about 3 hours to 4 hours with 250 mg administered every 12 hours but increased to 5 hours to 7 hours with 500 mg administered every 8 hours to 12 hours.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b98b02bb-2609-49a0-b29f-e5911aa0cbc1 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        The elimination half-life of clarithromycin was about 3 hours to 4 hours with 250 mg administered every 12 hours but increased to 5 hours to 7 hours with 500 mg administered every 8 hours to 12 hours.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d836ae7e-fdbf-4dcb-a90d-ede1dcbc3e67 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        The elimination half-life of clarithromycin was about 3 hours to 4 hours with 250 mg administered every 12 hours but increased to 5 hours to 7 hours with 500 mg administered every 8 hours to 12 hours.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:71a836d0-d60f-6418-e053-2a95a90aa6ef (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        Elimination half-life of clarithromycin (3 hours to 4 hours) and that of 14-OH clarithromycin (5 hours to 7 hours) were similar to those observed at steady state following administration of equivalent doses of clarithromycin immediate-release tablets.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9aaffb41-408c-4372-8fd5-1d649450c0e9 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        The elimination half-life of clarithromycin was about 3 hours to 4 hours with 250 mg administered every 12 hours but increased to 5 hours to 7 hours with 500 mg administered every 8 hours to 12 hours.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2d6cfd87-9b8c-bba9-e063-6294a90aff5a (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        The elimination half-life of clarithromycin was about 3 hours to 4 hours with 250 mg administered every 12 hours but increased to 5 hours to 7 hours with 500 mg administered every 8 hours to 12 hours.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0c7d8391-50ef-4827-abe6-e0fc0c2f1636 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        The elimination half-life of clarithromycin was about 3 hours to 4 hours with 250 mg administered every 12 hours but increased to 5 hours to 7 hours with 500 mg administered every 8 hours to 12 hours.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:471f638a-9dd1-09d3-e063-6294a90a2d4f (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        The elimination half-life of clarithromycin was about 3 hours to 4 hours with 250 mg administered every 12 hours but increased to 5 hours to 7 hours with 500 mg administered every 8 hours to 12 hours.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:268d21f9-02c9-41b0-9487-7968ea12720d (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        The elimination half-life of clarithromycin was about 3 hours to 4 hours with 250 mg administered every 12 hours but increased to 5 hours to 7 hours with 500 mg administered every 8 hours to 12 hours.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9143b79c-4c79-43ac-e053-2995a90ad708 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        The elimination half-life of clarithromycin was about 3 hours to 4 hours with 250 mg administered every 12 hours but increased to 5 hours to 7 hours with 500 mg administered every 8 hours to 12 hours.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1d6f5a9d-51b2-4e0d-b573-ccf08fe6ea23 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        The elimination half-life of clarithromycin was about 3 hours to 4 hours with 250 mg administered every 12 hours but increased to 5 hours to 7 hours with 500 mg administered every 8 hours to 12 hours.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:81c0c69e-b1ae-42f3-9e85-09b8daa75d8d (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        The elimination half-life of clarithromycin was about 3 hours to 4 hours with 250 mg administered every 12 hours but increased to 5 hours to 7 hours with 500 mg administered every 8 hours to 12 hours.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:88c7ded8-333c-408d-b693-a72881710f59 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        The elimination half-life of clarithromycin was about 3 hours to 4 hours with 250 mg administered every 12 hours but increased to 5 hours to 7 hours with 500 mg administered every 8 hours to 12 hours.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0c4db97f-f4c9-4cac-9f12-9db1d967ebeb (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        The elimination half-life of clarithromycin was about 3 hours to 4 hours with 250 mg administered every 12 hours but increased to 5 hours to 7 hours with 500 mg administered every 8 hours to 12 hours.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ba216276-b0bd-420a-9e0d-090bdfcc2460 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        The elimination half-life of clarithromycin was about 3 hours to 4 hours with 250 mg administered every 12 hours but increased to 5 hours to 7 hours with 500 mg administered every 8 hours to 12 hours.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f98aacb4-2f01-3e94-e053-6294a90a9aa0 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        The elimination half-life of clarithromycin was about 3 hours to 4 hours with 250 mg administered every 12 hours but increased to 5 hours to 7 hours with 500 mg administered every 8 hours to 12 hours.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0be243c6-de02-45dd-8210-cab1bbc8dfa7 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        The elimination half-life of clarithromycin was about 3 hours to 4 hours with 250 mg administered every 12 hours but increased to 5 hours to 7 hours with 500 mg administered every 8 hours to 12 hours.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9d5848f0-e9f0-4112-a7ca-bcc8ea2e69c6 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        The elimination half-life of clarithromycin was about 3 hours to 4 hours with 250 mg administered every 12 hours but increased to 5 hours to 7 hours with 500 mg administered every 8 hours to 12 hours.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:59ebe6cb-c830-45c7-8242-52f9f42a90a0 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        The elimination half-life of clarithromycin was about 3 hours to 4 hours with 250 mg administered every 12 hours but increased to 5 hours to 7 hours with 500 mg administered every 8 hours to 12 hours.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d5be5f12-6392-4d7d-ab23-ebc205ac1a85 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        Elimination half-life of clarithromycin (3 hours to 4 hours) and that of 14-OH clarithromycin (5 hours to 7 hours) were similar to those observed at steady state following administration of equivalent doses of clarithromycin immediate-release tablets.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:27e02b77-4332-49e0-8d0c-a072cf5dff92 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        The elimination half-life of clarithromycin was about 3 hours to 4 hours with 250 mg administered every 12 hours but increased to 5 hours to 7 hours with 500 mg administered every 8 hours to 12 hours.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1cb8a78a-0f07-49e8-a23e-a77628006209 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        The elimination half-life of clarithromycin was about 3 hours to 4 hours with 250 mg administered every 12 hours but increased to 5 hours to 7 hours with 500 mg administered every 8 hours to 12 hours.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1d328f5d-73c1-4df7-a3df-71d0e0221181 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        Elimination half-life of clarithromycin (3 hours to 4 hours) and that of 14-OH clarithromycin (5 hours to 7 hours) were similar to those observed at steady state following administration of equivalent doses of clarithromycin immediate-release tablets.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d0a66646-6774-4fc6-9b26-a98c3a5df274 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        The elimination half-life of clarithromycin was about 3 hours to 4 hours with 250 mg administered every 12 hours but increased to 5 hours to 7 hours with 500 mg administered every 8 hours to 12 hours.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:de33ba3a-9df1-4076-8d5f-b603d2698096 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        The elimination half-life of clarithromycin was about 3 hours to 4 hours with 250 mg administered every 12 hours but increased to 5 hours to 7 hours with 500 mg administered every 8 hours to 12 hours.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1920f943-bbf1-cfd9-7475-96a35680a9e0 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        The elimination half-life of clarithromycin was about 3 hours to 4 hours with 250 mg administered every 12 hours but increased to 5 hours to 7 hours with 500 mg administered every 8 hours to 12 hours.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cde51c9f-f7b8-413f-8b8e-e56370cd5754 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        The elimination half-life of clarithromycin was about 3 hours to 4 hours with 250 mg administered every 12 hours but increased to 5 hours to 7 hours with 500 mg administered every 8 hours to 12 hours.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:adba78c2-9e51-4bed-8c6a-6f977f79c40c (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        The elimination half-life of clarithromycin was about 3 hours to 4 hours with 250 mg administered every 12 hours but increased to 5 hours to 7 hours with 500 mg administered every 8 hours to 12 hours.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d22bd12c-737b-4aab-e053-2995a90aff60 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        The elimination half-life of clarithromycin was about 3 hours to 4 hours with 250 mg administered every 12 hours but increased to 5 hours to 7 hours with 500 mg administered every 8 hours to 12 hours.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:25debd85-0840-4f8d-9898-027772061dd2 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        The elimination half-life of clarithromycin was about 3 hours to 4 hours with 250 mg administered every 12 hours but increased to 5 hours to 7 hours with 500 mg administered every 8 hours to 12 hours.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3ba1da51-ba5b-323f-e063-6294a90a0333 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        The elimination half-life of clarithromycin was about 3 hours to 4 hours with 250 mg administered every 12 hours but increased to 5 hours to 7 hours with 500 mg administered every 8 hours to 12 hours.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4d4303f8-88dd-8b88-e063-6394a90ab48f (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        Elimination half-life of clarithromycin (3 hours to 4 hours) and that of 14-OH clarithromycin (5 hours to 7 hours) were similar to those observed at steady state following administration of equivalent doses of clarithromycin immediate-release tablets.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:99d2fd6b-39ca-42f9-ad06-30e7fbc22c47 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        The elimination half-life of clarithromycin was about 3 hours to 4 hours with 250 mg administered every 12 hours but increased to 5 hours to 7 hours with 500 mg administered every 8 hours to 12 hours.
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:28f60574-4ecd-441c-aebe-5b1d18033ef6 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        The elimination half-life of clarithromycin was about 3 hours to 4 hours with 250 mg administered every 12 hours but increased to 5 hours to 7 hours with 500 mg administered every 8 hours to 12 hours.
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dea5bd78-7f93-4bc4-a2e4-1b021f5fe098 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        Elimination half-life of clarithromycin (3 hours to 4 hours) and that of 14-OH clarithromycin (5 hours to 7 hours) were similar to those observed at steady state following administration of equivalent doses of clarithromycin immediate-release tablets.
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4d42821d-ce7a-7d64-e063-6294a90a0875 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        The elimination half-life of clarithromycin was about 3 hours to 4 hours with 250 mg administered every 12 hours but increased to 5 hours to 7 hours with 500 mg administered every 8 hours to 12 hours.
    2. 3 to 4 hours

      Numeric value
      3
      Unit
      hours
      Source records
      2

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 2 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9eb306e0-ccfb-418c-82ca-204f20a788f7 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        The elimination half-life of clarithromycin was about 3 to 4 hours with 250 mg administered every 12 hours but increased to 5 to 7 hours with 500 mg administered every 8 to 12 hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b1bdf526-4f16-4130-b614-4cb678f060d7 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        The elimination half-life of clarithromycin was about 3 to 4 hours with 250 mg administered every 12 hours but increased to 5 to 7 hours with 500 mg administered every 8 to 12 hours.
  4. Projected row 314

    Medicine slug
    clarithromycin
    Compared field
    tMax
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    42
    Source count
    35
    Agreement rate
    1
    Recorded readings
    1. 2 to 3 hours

      Numeric value
      2
      Unit
      hours
      Source records
      35

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 35 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fa69ea92-0b41-43fb-918f-ed80e0dedf04 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        In non-fasting healthy human subjects (males and females), peak plasma concentrations were attained within 2 to 3 hours after oral dosing.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a12e4d38-e0f8-4467-a26c-bb25a342aa92 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        In non-fasting healthy human subjects (males and females), peak plasma concentrations were attained within 2 to 3 hours after oral dosing.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9bf207c0-86eb-4f3b-92e7-f65f3fccd5a7 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        In non-fasting healthy human subjects (males and females), peak plasma concentrations were attained within 2 to 3 hours after oral dosing.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b98b02bb-2609-49a0-b29f-e5911aa0cbc1 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        In non-fasting healthy human subjects (males and females), peak plasma concentrations were attained within 2 to 3 hours after oral dosing.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d836ae7e-fdbf-4dcb-a90d-ede1dcbc3e67 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        In non-fasting healthy human subjects (males and females), peak plasma concentrations were attained within 2 to 3 hours after oral dosing.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9aaffb41-408c-4372-8fd5-1d649450c0e9 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        In non-fasting healthy human subjects (males and females), peak plasma concentrations were attained within 2 to 3 hours after oral dosing.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2d6cfd87-9b8c-bba9-e063-6294a90aff5a (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        In non-fasting healthy human subjects (males and females), peak plasma concentrations were attained within 2 to 3 hours after oral dosing.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0c7d8391-50ef-4827-abe6-e0fc0c2f1636 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        In non-fasting healthy human subjects (males and females), peak plasma concentrations were attained within 2 to 3 hours after oral dosing.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:471f638a-9dd1-09d3-e063-6294a90a2d4f (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        In non-fasting healthy human subjects (males and females), peak plasma concentrations were attained within 2 to 3 hours after oral dosing.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:268d21f9-02c9-41b0-9487-7968ea12720d (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        In non-fasting healthy human subjects (males and females), peak plasma concentrations were attained within 2 to 3 hours after oral dosing.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9143b79c-4c79-43ac-e053-2995a90ad708 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        In non-fasting healthy human subjects (males and females), peak plasma concentrations were attained within 2 to 3 hours after oral dosing.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1d6f5a9d-51b2-4e0d-b573-ccf08fe6ea23 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        In non-fasting healthy human subjects (males and females), peak plasma concentrations were attained within 2 to 3 hours after oral dosing.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:81c0c69e-b1ae-42f3-9e85-09b8daa75d8d (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        In non-fasting healthy human subjects (males and females), peak plasma concentrations were attained within 2 to 3 hours after oral dosing.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:88c7ded8-333c-408d-b693-a72881710f59 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        In non-fasting healthy human subjects (males and females), peak plasma concentrations were attained within 2 to 3 hours after oral dosing.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0c4db97f-f4c9-4cac-9f12-9db1d967ebeb (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        In non-fasting healthy human subjects (males and females), peak plasma concentrations were attained within 2 to 3 hours after oral dosing.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ba216276-b0bd-420a-9e0d-090bdfcc2460 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        In non-fasting healthy human subjects (males and females), peak plasma concentrations were attained within 2 to 3 hours after oral dosing.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f98aacb4-2f01-3e94-e053-6294a90a9aa0 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        In non-fasting healthy human subjects (males and females), peak plasma concentrations were attained within 2 to 3 hours after oral dosing.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0be243c6-de02-45dd-8210-cab1bbc8dfa7 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        In non-fasting healthy human subjects (males and females), peak plasma concentrations were attained within 2 to 3 hours after oral dosing.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9d5848f0-e9f0-4112-a7ca-bcc8ea2e69c6 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        In non-fasting healthy human subjects (males and females), peak plasma concentrations were attained within 2 to 3 hours after oral dosing.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:59ebe6cb-c830-45c7-8242-52f9f42a90a0 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        In non-fasting healthy human subjects (males and females), peak plasma concentrations were attained within 2 to 3 hours after oral dosing.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:27e02b77-4332-49e0-8d0c-a072cf5dff92 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        In non-fasting healthy human subjects (males and females), peak plasma concentrations were attained within 2 to 3 hours after oral dosing.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1cb8a78a-0f07-49e8-a23e-a77628006209 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        In non-fasting healthy human subjects (males and females), peak plasma concentrations were attained within 2 to 3 hours after oral dosing.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9eb306e0-ccfb-418c-82ca-204f20a788f7 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        In nonfasting healthy human subjects (males and females), peak plasma concentrations were attained within 2 to 3 hours after oral dosing.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d0a66646-6774-4fc6-9b26-a98c3a5df274 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        In non-fasting healthy human subjects (males and females), peak plasma concentrations were attained within 2 to 3 hours after oral dosing.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:de33ba3a-9df1-4076-8d5f-b603d2698096 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        In non-fasting healthy human subjects (males and females), peak plasma concentrations were attained within 2 to 3 hours after oral dosing.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1920f943-bbf1-cfd9-7475-96a35680a9e0 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        In non-fasting healthy human subjects (males and females), peak plasma concentrations were attained within 2 to 3 hours after oral dosing.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cde51c9f-f7b8-413f-8b8e-e56370cd5754 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        In non-fasting healthy human subjects (males and females), peak plasma concentrations were attained within 2 to 3 hours after oral dosing.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:adba78c2-9e51-4bed-8c6a-6f977f79c40c (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        In non-fasting healthy human subjects (males and females), peak plasma concentrations were attained within 2 to 3 hours after oral dosing.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d22bd12c-737b-4aab-e053-2995a90aff60 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        In non-fasting healthy human subjects (males and females), peak plasma concentrations were attained within 2 to 3 hours after oral dosing. clarithrofigure2 Figure 2: Steady-State Clarithromycin Plasma Concentration-Time Profiles Distribution Clarithromycin and the 14-OH clarithromycin metabolite distribute readily into body tissues and fluids.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:25debd85-0840-4f8d-9898-027772061dd2 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        In non-fasting healthy human subjects (males and females), peak plasma concentrations were attained within 2 to 3 hours after oral dosing.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3ba1da51-ba5b-323f-e063-6294a90a0333 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        In non-fasting healthy human subjects (males and females), peak plasma concentrations were attained within 2 to 3 hours after oral dosing.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:99d2fd6b-39ca-42f9-ad06-30e7fbc22c47 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        In non-fasting healthy human subjects (males and females), peak plasma concentrations were attained within 2 to 3 hours after oral dosing.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:28f60574-4ecd-441c-aebe-5b1d18033ef6 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        In non-fasting healthy human subjects (males and females), peak plasma concentrations were attained within 2 to 3 hours after oral dosing.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b1bdf526-4f16-4130-b614-4cb678f060d7 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        In nonfasting healthy human subjects (males and females), peak plasma concentrations were attained within 2 to 3 hours after oral dosing.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4d42821d-ce7a-7d64-e063-6294a90a0875 (opens source in a new tab)

        Clarithromycin label

        Version not recorded · Effective date not recorded

        In non-fasting healthy human subjects (males and females), peak plasma concentrations were attained within 2 to 3 hours after oral dosing.
  5. Projected row 315

    Medicine slug
    clindamycin
    Compared field
    halfLife
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    158
    Source count
    102
    Agreement rate
    0.784314
    Recorded readings
    1. 2.4 hours

      Numeric value
      2.4
      Unit
      hours
      Source records
      80

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 80 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cd2ca915-5672-440d-a14e-b4d3b6a522f3 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2b13d66d-4f48-477e-ba32-20e85d0e708d (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:22bf9385-cad3-43a7-802f-131b6826b5a5 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1d760cb7-d166-6707-e063-6394a90a8850 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7537fbab-c792-4b77-8736-c24b69cf48ea (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e8167412-882e-4143-93c6-49e68adbcf16 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7b110bab-815e-4654-860b-b9142fd93d45 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4730ab20-09e2-d32a-e063-6394a90ae125 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d53a66bf-fdbd-4a12-8d8c-4e3ab94e9ef5 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9e68cb17-73d9-8a00-e053-2995a90a517f (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8af1493c-1f22-4629-a432-f8b0578189e1 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f2f08e98-f6c5-7c2d-e053-2995a90abe1e (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4f0ddf1a-eda6-8ca8-e063-6294a90a4102 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f9e6ed50-ad03-4a9e-8760-8733e04a058c (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b22be885-f441-473e-879a-862588dcf89d (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:de7001d1-8b83-4f8b-8e50-c07691021456 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fadc321a-2291-4268-936f-0743fdddbe7f (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:337870c6-11e0-4d1a-a26e-afe042ee08c3 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:63f26644-b7ab-98c1-e053-2a91aa0af5d3 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:07f5d841-9c58-4dd1-b0bc-e12553931c8e (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bea7de4c-c077-4535-96a0-f6b319120b0b (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2178249b-a9fe-5015-e063-6294a90a9ff4 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2de041be-1d36-ee95-e063-6294a90a2091 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9fe68a5a-487b-4119-9ee7-603948d732e4 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:adf8f0fa-f794-4e97-a7b3-16b55d9c9a68 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:df9a2a41-b132-4f43-8940-b2d773b1369a (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:afeb96ed-7c2e-72d3-e053-2995a90a4ed3 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7f7fc73a-86e1-4d3e-8c83-1c74621e4af4 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:18ef4551-4066-4765-90cb-285d7711cf61 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b43dc396-17ef-a523-e053-2a95a90ac872 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:09eea0ad-702f-4eea-bfb9-81effc76b22b (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:87db8bce-1b6f-4f1b-ab62-b3778c429b2e (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a69260bb-31b5-4f77-e053-2995a90a37e1 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1d562ae9-5a9a-4fed-8cc7-3f30fb40f957 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cd5a1db8-9ddf-4de3-b856-bc3e8fb29061 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2393251d-33b9-4274-9d04-27ec9968eaa1 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1dd9e6b0-bcf4-5bf4-e063-6394a90a10c2 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c6703df0-b41d-439f-8e0d-d30b3039b3f8 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f6f5c8b2-83a1-5362-e053-6394a90aaaad (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b2a810f1-c009-e973-e053-2a95a90ad5b0 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b2bd8402-c887-5bfd-e053-2a95a90a15d9 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:11e8dd9c-81fd-4e88-e063-6294a90af13e (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2290109b-45c9-1aab-e063-6294a90a673b (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c3f35f80-e4ae-95f5-e053-2995a90a1b64 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:427a0138-c2dd-cf0b-e063-6394a90af407 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ba9bd5cd-036b-4b0c-e053-2a95a90a332e (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2367340c-d297-4a3f-8253-6d27a0ed39cb (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a2f6fa76-a114-4104-e053-2a95a90a9e0b (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d1aa1e91-4ac8-40d1-9fc4-963e1c9c3278 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:47f76d99-2024-4531-a527-66c80deeeb37 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      51. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1dbd8448-c1e5-46df-8060-50ef82380445 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      52. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:24595bb3-07ea-4d5f-9bb3-2c2332a1fc62 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      53. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bde81d4b-ad21-cc09-e053-2995a90a8c01 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      54. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:158e6c0c-1ca3-49a6-84fd-54d8fde7c2a7 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      55. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3256c93b-f26c-aeb9-e063-6394a90ae9c2 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      56. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e4d91d51-b92e-4d3e-8379-f9463f450537 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      57. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8e66de7a-d9d4-4562-bc99-80489d482da4 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      58. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e08eea9e-464c-429e-9584-b768f5127767 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      59. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f7e51a42-bc9e-490f-b8d8-8765f0b5be46 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      60. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9fe44bdd-eb59-4b55-e053-2995a90a3183 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      61. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:12dea490-e179-f295-e063-6394a90af4aa (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      62. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f4c4fce0-0472-45a3-b4c6-192d97ca1818 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      63. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:678912ff-a0c1-171b-e053-2991aa0ad128 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      64. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0a0fbeae-2bc2-2402-e063-6394a90a97a0 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      65. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3bddb5d2-ddac-2f03-e063-6294a90aa68c (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      66. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ebdcd3ce-3140-4bf6-b8b8-468ead08d9a9 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      67. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:51dfa3fa-6f6a-4904-a8d3-b5938cf9c852 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      68. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9b9f898f-6a91-44f8-9508-f9ddfaad27bc (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      69. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1f1b9230-b8ef-b0e4-e063-6394a90afc47 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      70. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5f6a85c5-dca3-49b1-a029-3818a41d49bf (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      71. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f781897a-ab54-7373-e053-6294a90a89a3 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      72. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:600c5ac7-64f7-44ac-9e83-cc1036471eec (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      73. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d6e1a5f2-9dcb-49fb-a5b0-d7d543520ac3 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      74. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c46cac0a-0c36-02fa-e053-2995a90a772b (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      75. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fa084aad-07fa-44d2-8d01-d32f40acd2f3 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      76. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3f6b2c5a-e581-414f-bc9e-eaf66a5685cd (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      77. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:509a9bc3-0901-0874-e063-6294a90a8816 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      78. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7d3e6ec5-93e9-4ce0-8276-b19aa97eb772 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      79. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:535e7e17-d020-4aa6-e063-6294a90ae114 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
      80. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8e3c9cf6-ab39-4fb5-94e3-232880c47700 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion The average biological half-life is 2.4 hours.
    2. 3 hours

      Numeric value
      3
      Unit
      hours
      Source records
      18

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 18 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dc8b8a09-3eed-1998-e053-2995a90a2f60 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion Biologically inactive clindamycin phosphate disappears from the serum with 6 minutes of the average elimination half-life; however, the average serum elimination half-life of active clindamycin is about 3 hours in adults and 2½ hours in pediatric patients.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7a6967b3-5563-4bed-9eee-d400f800e799 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion Biologically inactive clindamycin phosphate disappears from the serum with 6 minutes of the average elimination half-life; however, the average serum elimination half-life of active clindamycin is about 3 hours in adults and 2½ hours in pediatric patients.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9e4fc2d5-985a-3734-e053-2995a90aef5b (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion Biologically inactive clindamycin phosphate disappears from the serum with 6 minutes of the average elimination half-life; however, the average serum elimination half-life of active clindamycin is about 3 hours in adults and 2½ hours in pediatric patients.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:12ee0720-9979-3162-e063-6394a90a8003 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion Biologically inactive clindamycin phosphate disappears from the serum with 6 minutes of the average elimination half-life; however, the average serum elimination half-life of active clindamycin is about 3 hours in adults and 2½ hours in pediatric patients.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9e545c9d-dc39-584c-e053-2995a90afda4 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion Biologically inactive clindamycin phosphate disappears from the serum with 6 minutes of the average elimination half-life; however, the average serum elimination half-life of active clindamycin is about 3 hours in adults and 2½ hours in pediatric patients.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1a42c3b2-90b5-4a78-9f18-fa789742b033 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion Biologically inactive clindamycin phosphate disappears from the serum with 6 minutes of the average elimination half-life; however, the average serum elimination half-life of active clindamycin is about 3 hours in adults and 2½ hours in pediatric patients.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9e549ceb-00e8-64b8-e053-2a95a90aef0f (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion Biologically inactive clindamycin phosphate disappears from the serum with 6 minutes of the average elimination half-life; however, the average serum elimination half-life of active clindamycin is about 3 hours in adults and 2½ hours in pediatric patients.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:406534a6-2234-4735-ba8f-7de4c87592e6 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion Biologically inactive clindamycin phosphate disappears from the serum with 6 minutes of the average elimination half-life; however, the average serum elimination half-life of active clindamycin is about 3 hours in adults and 2½ hours in pediatric patients.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8a4e2ba4-90e6-48e8-a943-0c5d3f169780 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion Biologically inactive clindamycin phosphate disappears from the serum with 6 minutes of the average elimination half-life; however, the average serum elimination half-life of active clindamycin is about 3 hours in adults and 2½ hours in pediatric patients.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:184acaee-6129-479e-850f-d89575b8b391 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion Biologically inactive clindamycin phosphate disappears from the serum with 6 minutes of the average elimination half-life; however, the average serum elimination half-life of active clindamycin is about 3 hours in adults and 2½ hours in pediatric patients.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:44fa506b-90ac-42de-831b-5f3f1a500fc0 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Biologically inactive clindamycin phosphate disappears from the serum with 6 minutes of the average elimination half-life; however, the average serum elimination half-life of active clindamycin is about 3 hours in adults and 2.5 hours in pediatric patients.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:05a75685-0af5-407c-ac57-e380c882b49d (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion Biologically inactive clindamycin phosphate disappears from the serum with 6 minutes of the average elimination half-life; however, the average serum elimination half-life of active clindamycin is about 3 hours in adults and 2½ hours in pediatric patients.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:38416189-844b-939f-e063-6394a90aa271 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion Biologically inactive clindamycin phosphate disappears from the serum with 6 minutes of the average elimination half-life; however, the average serum elimination half-life of active clindamycin is about 3 hours in adults and 2½ hours in pediatric patients.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:78832ac6-04c5-45e0-ae4d-f56d7920dda9 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion Biologically inactive clindamycin phosphate disappears from the serum with 6 minutes of the average elimination half-life; however, the average serum elimination half-life of active clindamycin is about 3 hours in adults and 2½ hours in pediatric patients.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:896a046f-95d0-100e-e053-2a95a90aa59c (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion Biologically inactive clindamycin phosphate disappears from the serum with 6 minutes of the average elimination half-life; however, the average serum elimination half-life of active clindamycin is about 3 hours in adults and 2½ hours in pediatric patients.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9e500a08-0339-eb6b-e053-2a95a90a130c (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion Biologically inactive clindamycin phosphate disappears from the serum with 6 minutes of the average elimination half-life; however, the average serum elimination half-life of active clindamycin is about 3 hours in adults and 2½ hours in pediatric patients.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a0a2eff7-b7de-42fe-8e5a-0cfbed38bb4b (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion Biologically inactive clindamycin phosphate disappears from the serum with 6 minutes of the average elimination half-life; however, the average serum elimination half-life of active clindamycin is about 3 hours in adults and 2½ hours in pediatric patients.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9e5365a0-dd47-264a-e053-2a95a90a7fb8 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        Excretion Biologically inactive clindamycin phosphate disappears from the serum with 6 minutes of the average elimination half-life; however, the average serum elimination half-life of active clindamycin is about 3 hours in adults and 2½ hours in pediatric patients.
    3. 1.5 to 2.6 hours

      Numeric value
      1.5
      Unit
      hours
      Source records
      3

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 3 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b52bdaf7-3b54-4165-9ab0-9dfa08170e47 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        The systemic half-life was 1.5 to 2.6 hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f9be442d-0782-4b93-828f-9ebbf67dbced (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        The systemic half-life was 1.5 to 2.6 hours.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:997a23c8-f0d7-49d5-af33-e11f2ddab3c7 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        The systemic half-life was 1.5 to 2.6 hours.
    4. 11 hours

      Numeric value
      11
      Unit
      hours
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3db26227-208d-4fdd-8426-1d9be5cda9b4 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        The mean apparent elimination half-life after dosing with the suppository was 11 hours (range 4 to 35 hours) and is considered to be limited by the absorption rate.
  6. Projected row 316

    Medicine slug
    clindamycin
    Compared field
    tMax
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    158
    Source count
    22
    Agreement rate
    0.818182
    Recorded readings
    1. 3 hours

      Numeric value
      3
      Unit
      hours
      Source records
      18

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 18 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dc8b8a09-3eed-1998-e053-2995a90a2f60 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        After intramuscular injection of clindamycin phosphate, peak concentrations of active clindamycin are reached within 3 hours in adults and 1 hour in pediatric patients.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7a6967b3-5563-4bed-9eee-d400f800e799 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        After intramuscular injection of clindamycin phosphate, peak concentrations of active clindamycin are reached within 3 hours in adults and 1 hour in pediatric patients.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9e4fc2d5-985a-3734-e053-2995a90aef5b (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        After intramuscular injection of clindamycin phosphate, peak concentrations of active clindamycin are reached within 3 hours in adults and 1 hour in pediatric patients.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:12ee0720-9979-3162-e063-6394a90a8003 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        After intramuscular injection of clindamycin phosphate, peak concentrations of active clindamycin are reached within 3 hours in adults and 1 hour in pediatric patients.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9e545c9d-dc39-584c-e053-2995a90afda4 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        After intramuscular injection of clindamycin phosphate, peak concentrations of active clindamycin are reached within 3 hours in adults and 1 hour in pediatric patients.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1a42c3b2-90b5-4a78-9f18-fa789742b033 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        After intramuscular injection of clindamycin phosphate, peak concentrations of active clindamycin are reached within 3 hours in adults and 1 hour in pediatric patients.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9e549ceb-00e8-64b8-e053-2a95a90aef0f (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        After intramuscular injection of clindamycin phosphate, peak concentrations of active clindamycin are reached within 3 hours in adults and 1 hour in pediatric patients.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:406534a6-2234-4735-ba8f-7de4c87592e6 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        After intramuscular injection of clindamycin phosphate, peak concentrations of active clindamycin are reached within 3 hours in adults and 1 hour in pediatric patients.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8a4e2ba4-90e6-48e8-a943-0c5d3f169780 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        After intramuscular injection of clindamycin phosphate, peak concentrations of active clindamycin are reached within 3 hours in adults and 1 hour in pediatric patients.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:184acaee-6129-479e-850f-d89575b8b391 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        After intramuscular injection of clindamycin phosphate, peak concentrations of active clindamycin are reached within 3 hours in adults and 1 hour in pediatric patients.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:44fa506b-90ac-42de-831b-5f3f1a500fc0 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        After intramuscular injection of clindamycin phosphate, peak concentrations of active clindamycin are reached within 3 hours in adults and 1 hour in pediatric patients.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:05a75685-0af5-407c-ac57-e380c882b49d (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        After intramuscular injection of clindamycin phosphate, peak concentrations of active clindamycin are reached within 3 hours in adults and 1 hour in pediatric patients.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:38416189-844b-939f-e063-6394a90aa271 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        After intramuscular injection of clindamycin phosphate, peak concentrations of active clindamycin are reached within 3 hours in adults and 1 hour in pediatric patients.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:78832ac6-04c5-45e0-ae4d-f56d7920dda9 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        After intramuscular injection of clindamycin phosphate, peak concentrations of active clindamycin are reached within 3 hours in adults and 1 hour in pediatric patients.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:896a046f-95d0-100e-e053-2a95a90aa59c (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        After intramuscular injection of clindamycin phosphate, peak concentrations of active clindamycin are reached within 3 hours in adults and 1 hour in pediatric patients.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9e500a08-0339-eb6b-e053-2a95a90a130c (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        After intramuscular injection of clindamycin phosphate, peak concentrations of active clindamycin are reached within 3 hours in adults and 1 hour in pediatric patients.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a0a2eff7-b7de-42fe-8e5a-0cfbed38bb4b (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        After intramuscular injection of clindamycin phosphate, peak concentrations of active clindamycin are reached within 3 hours in adults and 1 hour in pediatric patients.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9e5365a0-dd47-264a-e053-2a95a90a7fb8 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        After intramuscular injection of clindamycin phosphate, peak concentrations of active clindamycin are reached within 3 hours in adults and 1 hour in pediatric patients.
    2. 10 hours

      Numeric value
      10
      Unit
      hours
      Source records
      3

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 3 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b52bdaf7-3b54-4165-9ab0-9dfa08170e47 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        These peak concentrations were attained approximately 10 hours post-dosing (range 4–24 hours).
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f9be442d-0782-4b93-828f-9ebbf67dbced (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        These peak concentrations were attained approximately 10 hours post-dosing (range 4–24 hours).
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:997a23c8-f0d7-49d5-af33-e11f2ddab3c7 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        These peak concentrations were attained approximately 10 hours post-dosing (range 4 to 24 hours).
    3. 6 hours

      Numeric value
      6
      Unit
      hours
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0423007f-28fa-4159-bf58-9174626d2347 (opens source in a new tab)

        Clindamycin label

        Version not recorded · Effective date not recorded

        The median (range) t max occurred at 6 hours (4 to 96 hours).
  7. Projected row 317

    Medicine slug
    clobazam
    Compared field
    bioavailability
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    22
    Source count
    21
    Agreement rate
    1
    Recorded readings
    1. 100%

      Numeric value
      100
      Unit
      %
      Source records
      21

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 21 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:574a3f91-d73e-46bc-b4a1-2388439521fb (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The relative bioavailability of clobazam tablets compared to an oral solution is approximately 100%.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6f94e10e-ee4e-44e1-9c84-16c5d8c9b594 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The relative bioavailability of clobazam tablets compared to an oral solution is approximately 100%.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8fce3252-95f8-4428-9922-5ba308e20177 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The relative bioavailability of clobazam tablets compared to an oral solution is approximately 100%.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:75fcff4a-1b35-4d92-8477-ff5ce7427f5f (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The relative bioavailability of clobazam tablets compared to an oral solution is approximately 100%.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:17c3b9db-9e25-4a17-ac45-bcd17ea0360c (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The relative bioavailability of clobazam tablets compared to an oral solution is approximately 100%.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6332e71c-3b37-422c-838c-8a2489ac6009 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The relative bioavailability of clobazam tablets compared to an oral solution is approximately 100%.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cf5bb37f-5386-47d3-8cec-d48253d359f6 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The relative bioavailability of clobazam tablets compared to an oral solution is approximately 100%.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cf31b8d1-0d19-4529-99b6-1f7366064a3c (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The relative bioavailability of clobazam tablets compared to an oral solution is approximately 100%.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2166ea46-28ff-f492-e063-6394a90a4a45 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The relative bioavailability of clobazam tablets compared to an oral solution is approximately 100%.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:de03bd69-2dca-459c-93b4-541fd3e9571c (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The relative bioavailability of clobazam tablets compared to an oral solution is approximately 100%.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:721dde68-db83-4dad-8649-8046cb455372 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The relative bioavailability of clobazam tablets compared to an oral solution is approximately 100%.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4b92ac57-25aa-4c00-b062-dee3944b271b (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The relative bioavailability of clobazam tablets compared to an oral solution is approximately 100%.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a77ffbdd-4e3e-4ec4-b0fa-b51ee610df0f (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The relative bioavailability of clobazam tablets compared to an oral solution is approximately 100%.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6783eaa8-e236-4957-aaa9-b42bf8e709a7 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The relative bioavailability of clobazam tablets compared to an oral solution is approximately 100%.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c9b51794-3cfa-4a34-b5bb-d523b5798c17 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The relative bioavailability of clobazam tablets compared to an oral suspension is approximately 100%.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:07e0ae51-cc71-427f-83cb-311b7fcc5993 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The relative bioavailability of clobazam tablets compared to an oral solution is approximately 100%.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1b5749a1-1c6d-4243-a833-4bfd84f9d5a9 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The relative bioavailability of clobazam tablets compared to an oral solution is approximately 100%.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d9e03a2a-3fea-4c98-ab71-415e6ebda3e0 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The relative bioavailability of clobazam tablets compared to an oral solution is approximately 100%.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fd1e63bf-496c-427c-83b7-6acabc00a5e5 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The relative bioavailability of clobazam tablets compared to an oral solution is approximately 100%.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6da2c381-057b-456a-b57b-464f8b383371 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The relative bioavailability of clobazam tablets compared to an oral solution is approximately 100%.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a526ad73-d3c1-40b7-8e71-426b01cdea27 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The relative bioavailability of clobazam tablets compared to an oral solution is approximately 100%.
  8. Projected row 318

    Medicine slug
    clobazam
    Compared field
    proteinBinding
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    22
    Source count
    22
    Agreement rate
    0.590909
    Recorded readings
    1. 80 to 90%

      Numeric value
      80
      Unit
      %
      Source records
      13

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 13 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:574a3f91-d73e-46bc-b4a1-2388439521fb (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The in vitro plasma protein binding of clobazam and N-desmethylclobazam is approximately 80 to 90% and 70%, respectively.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6f94e10e-ee4e-44e1-9c84-16c5d8c9b594 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The in vitro plasma protein binding of clobazam and N-desmethylclobazam is approximately 80 to 90% and 70%, respectively.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5e3d8fcb-aa7d-4822-88fc-4f06264c3242 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The in vitro plasma protein binding of clobazam and N-desmethylclobazam is approximately 80-90% and 70%, respectively.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:75fcff4a-1b35-4d92-8477-ff5ce7427f5f (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The in vitro plasma protein binding of clobazam and N-desmethylclobazam is approximately 80 to 90% and 70%, respectively.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:17c3b9db-9e25-4a17-ac45-bcd17ea0360c (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The in vitro plasma protein binding of clobazam and N-desmethylclobazam is approximately 80-90% and 70%, respectively.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cf5bb37f-5386-47d3-8cec-d48253d359f6 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The in vitro plasma protein binding of clobazam and N-desmethylclobazam is approximately 80-90% and 70%, respectively.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cf31b8d1-0d19-4529-99b6-1f7366064a3c (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The in vitro plasma protein binding of clobazam and N-desmethylclobazam is approximately 80 to 90% and 70%, respectively.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:de03bd69-2dca-459c-93b4-541fd3e9571c (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The in vitro plasma protein binding of clobazam and N-desmethylclobazam is approximately 80-90% and 70%, respectively.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:721dde68-db83-4dad-8649-8046cb455372 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The in vitro plasma protein binding of clobazam and N-desmethylclobazam is approximately 80 to 90% and 70%, respectively.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c9b51794-3cfa-4a34-b5bb-d523b5798c17 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The in vitro plasma protein binding of clobazam and N-desmethylclobazam is approximately 80 to 90% and 70%, respectively.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1b5749a1-1c6d-4243-a833-4bfd84f9d5a9 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The in vitro plasma protein binding of clobazam and N-desmethylclobazam is approximately 80 to 90% and 70%, respectively.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d9e03a2a-3fea-4c98-ab71-415e6ebda3e0 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The in vitro plasma protein binding of clobazam and N-desmethylclobazam is approximately 80 to 90% and 70%, respectively.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fd1e63bf-496c-427c-83b7-6acabc00a5e5 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The in vitro plasma protein binding of clobazam and N-desmethylclobazam is approximately 80 to 90% and 70%, respectively.
    2. 80%

      Numeric value
      80
      Unit
      %
      Source records
      9

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 9 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8fce3252-95f8-4428-9922-5ba308e20177 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The in vitro plasma protein binding of clobazam and N-desmethylclobazam is approximately 80% to 90% and 70%, respectively.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6332e71c-3b37-422c-838c-8a2489ac6009 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The in vitro plasma protein binding of clobazam and N-desmethylclobazam is approximately 80% to 90% and 70%, respectively.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2166ea46-28ff-f492-e063-6394a90a4a45 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The in vitro plasma protein binding of clobazam and N-desmethylclobazam is approximately 80% to 90% and 70%, respectively.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4b92ac57-25aa-4c00-b062-dee3944b271b (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The in vitro plasma protein binding of clobazam and N-desmethylclobazam is approximately 80% to 90% and 70%, respectively.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a77ffbdd-4e3e-4ec4-b0fa-b51ee610df0f (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The in vitro plasma protein binding of clobazam and N-desmethylclobazam is approximately 80% to 90% and 70%, respectively.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6783eaa8-e236-4957-aaa9-b42bf8e709a7 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The in vitro plasma protein binding of clobazam and N-desmethylclobazam is approximately 80% to 90% and 70%, respectively.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:07e0ae51-cc71-427f-83cb-311b7fcc5993 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The in vitro plasma protein binding of clobazam and N-desmethylclobazam is approximately 80% to 90% and 70%, respectively.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6da2c381-057b-456a-b57b-464f8b383371 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The in vitro plasma protein binding of clobazam and N-desmethylclobazam is approximately 80% to 90% and 70%, respectively.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a526ad73-d3c1-40b7-8e71-426b01cdea27 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The in vitro plasma protein binding of clobazam and N-desmethylclobazam is approximately 80% to 90% and 70%, respectively.
  9. Projected row 319

    Medicine slug
    clobazam
    Compared field
    volumeOfDistribution
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    22
    Source count
    22
    Agreement rate
    1
    Recorded readings
    1. 100 L

      Numeric value
      100
      Unit
      L
      Source records
      22

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 22 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:574a3f91-d73e-46bc-b4a1-2388439521fb (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state was approximately 100 L.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6f94e10e-ee4e-44e1-9c84-16c5d8c9b594 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state was approximately 100 L.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8fce3252-95f8-4428-9922-5ba308e20177 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady-state was approximately 100 L.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5e3d8fcb-aa7d-4822-88fc-4f06264c3242 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state was approximately 100 L.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:75fcff4a-1b35-4d92-8477-ff5ce7427f5f (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state was approximately 100 L.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:17c3b9db-9e25-4a17-ac45-bcd17ea0360c (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state was approximately 100 L.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6332e71c-3b37-422c-838c-8a2489ac6009 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady-state was approximately 100 L.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cf5bb37f-5386-47d3-8cec-d48253d359f6 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state was approximately 100 L.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cf31b8d1-0d19-4529-99b6-1f7366064a3c (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state was approximately 100 L.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2166ea46-28ff-f492-e063-6394a90a4a45 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state was approximately 100 L.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:de03bd69-2dca-459c-93b4-541fd3e9571c (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state was approximately 100 L.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:721dde68-db83-4dad-8649-8046cb455372 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state was approximately 100 L.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4b92ac57-25aa-4c00-b062-dee3944b271b (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state was approximately 100 L.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a77ffbdd-4e3e-4ec4-b0fa-b51ee610df0f (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state was approximately 100 L.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6783eaa8-e236-4957-aaa9-b42bf8e709a7 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady-state was approximately 100 L.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c9b51794-3cfa-4a34-b5bb-d523b5798c17 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state was approximately 100 L.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:07e0ae51-cc71-427f-83cb-311b7fcc5993 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state was approximately 100 L.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1b5749a1-1c6d-4243-a833-4bfd84f9d5a9 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state was approximately 100 L.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d9e03a2a-3fea-4c98-ab71-415e6ebda3e0 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state was approximately 100 L.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fd1e63bf-496c-427c-83b7-6acabc00a5e5 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state was approximately 100 L.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6da2c381-057b-456a-b57b-464f8b383371 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady state was approximately 100 L.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a526ad73-d3c1-40b7-8e71-426b01cdea27 (opens source in a new tab)

        Clobazam label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution at steady-state was approximately 100 L.
  10. Projected row 320

    Medicine slug
    clofarabine
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    7
    Source count
    7
    Agreement rate
    1
    Recorded readings
    1. 5.2 hours

      Numeric value
      5.2
      Unit
      hours
      Source records
      7

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 7 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54436453-882e-406b-87a3-049d150101c6 (opens source in a new tab)

        Clofarabine label

        Version not recorded · Effective date not recorded

        The terminal half-life was 5.2 hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b7d3a96e-0280-4f14-b921-795996f75950 (opens source in a new tab)

        Clofarabine label

        Version not recorded · Effective date not recorded

        The terminal half-life was 5.2 hours.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0a273a2d-a1ff-412a-925e-696648730dae (opens source in a new tab)

        Clofarabine label

        Version not recorded · Effective date not recorded

        The terminal half-life was 5.2 hours.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fe6ff0f9-7610-4a69-9b75-da7ec4bb7744 (opens source in a new tab)

        Clofarabine label

        Version not recorded · Effective date not recorded

        The terminal half-life was 5.2 hours.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:18adf4af-63ed-41e6-ab59-87085ce3e5fb (opens source in a new tab)

        Clofarabine label

        Version not recorded · Effective date not recorded

        The terminal half-life was 5.2 hours.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e956b1e0-2829-4872-8c09-99462d60e922 (opens source in a new tab)

        Clofarabine label

        Version not recorded · Effective date not recorded

        The terminal half-life was 5.2 hours.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0da6764d-5fac-7e0f-ea3e-a5aee55a8b2d (opens source in a new tab)

        Clofarabine label

        Version not recorded · Effective date not recorded

        The terminal half-life was 5.2 hours.

Access

Query or download the projection

GET /api/datasets/source-consensus?limit=10&offset=310

Allowed query parameters

q
Case-insensitive text search over the public fields named for this dataset.
state
Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
field
Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
limit / offset
Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.

Reuse and corrections

Keep the boundary attached

CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.

Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.

Read the correction policy